Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
TransThera Sciences (Nanjing) FCF Yield % Related Terms
TransThera Sciences (Nanjing) FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) FCF Yield % Chart
TransThera Sciences (Nanjing) Annual Data
Trend
Dec23
Dec24
Dec25
FCF Yield %
0.00
0.00
0.00
TransThera Sciences (Nanjing) Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
FCF Yield %
0.00
0.00
0.00
0.00
0.00
FRA:J8J vs VRTX, REGN, RVMD: FCF Yield % Comparison
For the Biotechnology subindustry, TransThera Sciences (Nanjing)'s FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransThera Sciences (Nanjing) FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TransThera Sciences (Nanjing)'s FCF Yield % distribution charts can be found below:
* The bar in red indicates where TransThera Sciences (Nanjing)'s FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransThera Sciences (Nanjing) (FRA:J8J) has a FCF Yield % of -6.70 as of Aug. 22, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on TransThera Sciences (Nanjing) and its competitors. According to the industry distribution chart, TransThera Sciences (Nanjing) ranks #608 out of 1410 companies in the Biotechnology industry, placing it in the top 43.1%.
Is TransThera Sciences (Nanjing)'s FCF Yield % too high?
TransThera Sciences (Nanjing)'s current FCF Yield % is -6.70. Based on the distribution chart, TransThera Sciences (Nanjing) ranks #608 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint. Overall, TransThera Sciences (Nanjing) has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does TransThera Sciences (Nanjing)'s FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, TransThera Sciences (Nanjing) ranks #608 out of 1410 companies for FCF Yield %. This puts TransThera Sciences (Nanjing) in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on TransThera Sciences (Nanjing) and its competitors. TransThera Sciences (Nanjing)'s current FCF Yield % is -6.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransThera Sciences (Nanjing) stock overvalued right now?
TransThera Sciences (Nanjing) (FRA:J8J) has a current FCF Yield % of -6.70. The current FCF Yield % is -6.70. TransThera Sciences (Nanjing)'s overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For TransThera Sciences (Nanjing) (FRA:J8J), the current FCF Yield % is -6.70 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its core Product Tinengotinib is a multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
20GF Score
Get the complete analysis for FRA:J8J
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:J8J has been successfully added to your 
